Novartis is to pay US$75 M upfront for the worldwide rights to elinogrel, an anti-platelet drug developed by Portola Pharmaceuticals. In early clinical trials the drug demonstrated several clinical advantages over the current standard treatment, Plavix®, and could fill a significant treatment gap.